top of page
Modern Architecture
Search

AI in Health Care: Moving Beyond the Hype to Transform Care Delivery


What if artificial intelligence (AI) could identify a deadly infection 12 hours before a doctor notices the first symptoms?


That's not science fiction. It's happening right now in emergency departments across the U.S., and the implications for insurers, health care marketers, and the entire care delivery ecosystem are profound.


Key Takeaways:


  • Health systems have transitioned from pilot programs to enterprise-wide clinical AI deployments with measurable patient outcomes

  • Tampa General Hospital achieved a 68% reduction in sepsis mortality rates, saving nearly 800 lives over three years using AI monitoring

  • Mayo Clinic's AI models detect pancreatic cancer up to three years earlier than traditional methods, with 92% accuracy

  • The average health system could see 40-50% efficiency improvements in prior authorization and claims processing through AI automation

  • 84% of major health insurers now use AI operationally, creating new dynamics for claims management and utilization review

  • Clinical AI adoption remains cautious due to ROI uncertainty, but health systems deploying AI report significant cost savings alongside improved outcomes

  • The regulatory landscape is fragmenting across states, creating compliance complexity but also innovation opportunities


The question is whether stakeholders can adapt quickly enough to this new reality.


Numbers Tell a Story: Clinical AI Is Delivering Real Results

The health care industry crossed a critical threshold in 2025. According to recent data, 66% of U.S. physicians now use AI in their practice, up from just 38% in 2023.


This represents a 78% increase in a single year. Meanwhile, 71% of U.S. hospitals run at least one electronic health record (EHR)-integrated predictive AI tool, signaling that AI has evolved from experimental technology to standard infrastructure.


The global AI health care market reached approximately $39.25 billion in 2025 and is projected to climb to $504.17 billion by the early 2030s. North America holds nearly 50% of this market, meaning U.S. health systems, payers, and life sciences companies will write a significant portion of this growth story.


But these market figures only hint at what's happening on the ground, where patients are experiencing tangibly different outcomes because of AI deployment.


Case Study Deep Dive: How Five Health Systems Are Using Clinical AI

The most compelling evidence for clinical AI comes not from vendor white papers or conference presentations, but from health systems that have moved beyond pilot programs to enterprise-wide deployments with measurable patient outcomes. These organizations represent different care delivery models, patient populations, and geographic regions, but share a common thread: they're using AI to solve specific clinical problems with documented results.


The following five health systems presented their AI initiatives at the January 2026 J.P. Morgan Healthcare Conference. Their experiences offer concrete insights into what works, what challenges remain, and how clinical AI is reshaping care delivery in ways that directly impact insurance carriers, agents, and health care marketers.


Tampa General Hospital: AI-Powered Sepsis Surveillance Changes Mortality Equations

Sepsis kills approximately 350,000 Americans annually, making it one of the deadliest conditions in hospital settings. The window for effective intervention is measured in hours, and traditional monitoring methods often miss critical early warning signs.


Tampa General Hospital deployed AI-powered predictive analytics to continuously monitor sepsis patients, analyzing patterns in vital signs, lab results, and other clinical indicators that human observers might miss during shift changes or high-volume periods. The system flags unexpected changes and sends alerts to clinicians when it identifies early infection signs.


The results validate AI's clinical potential. Between 2022 and 2025, Tampa General Hospital reduced its 48-hour sepsis mortality rate by 68%, translating to nearly 800 lives saved.


CEO John Couris emphasized the dual benefit: improved patient outcomes alongside reduced costs. Late-stage sepsis treatment can exceed $20,000 per patient, with severe cases reaching six figures.


This matters enormously for insurance carriers. Sepsis-related claims represent a significant cost driver, and AI that prevents progression to critical stages directly impacts both claim volumes and severity.


A 2024 study on the COMPOSER deep-learning model at UC San Diego Health found similar results: a 17% relative decrease in sepsis mortality, a 10% increase in treatment bundle compliance, and reduced organ dysfunction at 72 hours postonset. Duke Health's Sepsis Watch system, integrated since 2018, achieved a 27% reduction in sepsis deaths.


The insurance implications extend beyond immediate cost savings. Health systems deploying effective sepsis AI will generate different utilization patterns: more diagnostic interventions upfront, but fewer catastrophic late-stage treatments.


Mayo Clinic: Detecting the Undetectable Years in Advance

Pancreatic cancer has earned its reputation as one of medicine's deadliest challenges. By the time symptoms appear, the disease is usually advanced.


The five-year survival rate stands at just 13% overall though it increases to 44% when detected early and confined to the pancreas. The problem is that only 7% of pancreatic cancers are caught at this stage.


Mayo Clinic researchers addressed this by training AI models on more than 3,000 patient CT scans. Their AI tool can detect pancreatic cancer with 92% accuracy at a median of 438 days before clinical diagnosis, with some cases as early as three years in advance.


Dr. Ajit Goenka, radiologist and nuclear medicine specialist at Mayo Clinic, explained that small pancreatic tumors look nearly identical to healthy pancreatic tissue on imaging. A human radiologist could spend 20 to 30 minutes analyzing a single scan and still miss subtle abnormalities. AI, however, processes the same scan in a fraction of a second with greater accuracy.


For insurers and health care marketers, this represents a fundamental shift in cancer care economics. Early-stage pancreatic cancer treatment—typically surgical resection with adjuvant therapy—costs significantly less than late-stage management involving extensive chemotherapy, palliative care, and end-of-life services. Patients whose survival was measured in months could potentially live for years or decades.


Mayo Clinic has also developed AI-assisted tools for electrocardiogram (ECG) screening that identifies life-threatening heart conditions without obvious symptoms. Its AI model for contouring radiation treatment in head and neck cancer patients reduced radiologists' work effort by 76%.


Mayo Clinic has initiated clinical validation trials and is moving these models through regulatory processes. The pancreatic cancer early detection trial is expected to screen 10,000 patients to identify those at elevated risk.


Henry Ford Health: Pharmacogenomics Meets Predictive Analytics

The Detroit-based health system is applying AI to analyze genetic information and predict patient responses to specific medications before administration. The system can forecast whether patients will experience unexpected complications from blood thinners or whether the drugs will prove ineffective based on their genetic profile.


This pharmacogenomic approach is valuable for patients taking multiple medications including those managing behavioral health conditions. Dr. Adnan Munkarah, chief physician executive at Henry Ford , pointed out that this analysis helps to control costs, reduce potential side effects, and improve outcomes.


The insurance implications are substantial. Adverse drug events cost the health care system billions annually, with preventable adverse drug events in hospitals alone costing approximately $3.5 billion per year.


AI that prevents these events before they occur reduces both immediate treatment costs and downstream complications.


For commercial insurers, this technology could transform pharmacy benefit management. Instead of reactive step therapy protocols that patients must fail before accessing alternative medications, AI could enable proactive matching of patients to effective therapies from the start.


Robin Damschroder, Henry Ford Health's chief financial officer, emphasized that better medication management reduces both direct pharmaceutical costs and the broader expenses associated with ineffective treatments and adverse events.


Cleveland Clinic: AI-Accelerated Drug Development

The academic health system has integrated AI with quantum computing to simulate drug interactions and effectiveness within the human body. This computational approach can compress drug development timelines and improve early-stage predictions about which compounds will prove therapeutically valuable.


Cleveland Clinic President and CEO Tom Mihaljevic explained that AI and machine learning (ML)-assisted quantum computing can model how drugs will affect someone's body and predict effectiveness, potentially accelerating the entire research and development pipeline.

For insurance carriers, especially those with pharmacy benefit management arms, this represents both opportunity and challenge. Faster drug development could bring more treatment options to market more quickly, but it also means more rapid evolution in treatment protocols.


The broader implication is that health systems are positioning themselves not just as care delivery organizations but as research and development (R&D) engines. This could shift the competitive dynamics of health care innovation.


Advocate Health: AI for Patient Safety Infrastructure

Charlotte, North Carolina-based Advocate Health has deployed AI-powered cameras and sensors in patient rooms to reduce falls. CEO Eugene Woods emphasized how this technology helps keep patients safe, a priority that aligns with both quality metrics and cost management.


Patient falls represent a significant quality and financial burden. Beyond the immediate medical consequences, falls extend hospital stays, increase complication rates, and trigger penalties under Medicare's Hospital-Acquired Condition Reduction Program. Hospitals in the worst-performing quartile lose 1% of their Medicare payments.


AI-based fall prevention systems analyze patient movement patterns and environmental factors to predict fall risk in real time, enabling preemptive interventions. For insurers, this technology reduces claim severity for hospital-acquired injuries and supports value-based care arrangements that reward quality outcomes.


Cautious Approach: Why ROI Matters More for Clinical AI

Despite these success stories, health system executives maintain measured expectations about clinical AI expansion. Rob Allen, president and CEO of Intermountain Health, articulated the prevailing wisdom: back-office applications like revenue cycle management and clinical documentation are "no-regret moves" with clear return on investment (ROI).


Clinical applications require more careful evaluation. This caution stems from several factors that insurance stakeholders should understand.


Uncertain Financial Returns

Administrative AI delivers measurable efficiency gains within months. Automated coding reduces days in accounts receivable, and AI-powered prior authorization tools cut processing time.


Clinical AI benefits may take years to quantify. Reduced sepsis mortality improves quality metrics and potentially reduces readmissions, but the financial impact depends on payment models.


Under fee-for-service contracts, preventing complications could actually reduce revenue. Under value-based arrangements, it improves margins.


Limited Clinical Validation

Many AI tools lack the extensive prospective validation that characterizes traditional medical devices. The Food and Drug Administration (FDA) has cleared 1,357 AI-enabled medical devices as of late 2025, but few have undergone large-scale randomized controlled trials demonstrating clinical superiority over standard care.


The State of Clinical AI report from Stanford and Harvard, released in January 2026, highlighted this gap. While several studies showed large language models matching or outperforming physicians on diagnostic reasoning when evaluated on fixed clinical cases, real-world performance often differs from controlled research settings.


External validation across diverse settings remains critical to establish reliability before clinical integration.


Integration Complexity

Clinical AI must integrate seamlessly into existing workflows without creating new burdens for already-stressed clinicians. A 2026 industry survey found that 71% of hospitals use EHR-integrated predictive AI, but integration quality varies dramatically.


Poorly designed AI tools can increase cognitive burden, generate alert fatigue, or introduce new failure points in clinical processes. Despite widespread adoption, the Epic Sepsis Model (ESM), a widely adopted AI tool that's embedded in Epic's EHR system, has shown low sensitivity and high false alarm rates in some implementations.


What This Means for Insurance Carriers: Six Strategic Implications

The clinical AI deployments at Tampa General Hospital, Mayo Clinic, and other leading health systems represent the leading edge of a transformation that will reshape how health care is delivered, how costs are managed, and how risk is distributed across the health care ecosystem. Insurance carriers face both opportunities and challenges as AI adoption accelerates.


Understanding these implications now allows carriers to adjust actuarial models, refine network strategies, and position products ahead of market shifts rather than reacting to them. Here are six strategic areas requiring immediate attention:


  • Actuarial models need recalibration—Health systems deploying clinical AI will generate different utilization patterns. Earlier disease detection may increase diagnostic procedure volumes initially, but reduce expensive late-stage treatments over time. According to PwC's 2026 medical cost trend analysis, AI's diagnostic strength could drive up medical cost trend in the short term as providers see more patients. Carriers should evaluate how AI-enabled care pathways affect their models and risk adjustment approaches.

  • Prior authorization will evolve quickly—McKinsey research indicates that AI-enabled prior authorization can automate 50% to 75% of manual tasks. However, Stanford researchers have raised concerns about the lack of meaningful human review in AI-driven utilization management decisions. A 2024 survey found that 84% of large health insurers were using AI operationally, but governance processes often lag behind deployment. Texas and California have already passed laws requiring transparency when AI influences high-risk decisions, with enforcement having begun on January 1, 2026.

  • Value-based arrangements will favor AI adopters—Health systems that successfully deploy clinical AI will improve quality metrics, reduce complications, and lower total cost of care. For carriers developing accountable care organization partnerships or bundled payment arrangements, AI capability should become an evaluation criterion. Systems that can demonstrate measurable outcomes from AI deployment represent lower-risk partners for shared savings agreements.

  • Pharmacy benefit management faces disruption—AI-driven pharmacogenomics could transform pharmacy benefit design by enabling proactive genetic testing to match patients with effective medications from the start. This approach requires different benefit structures and potentially higher upfront testing costs, but it could reduce overall pharmaceutical spending. Several carriers are already piloting pharmacogenomic testing for specific drug classes.

  • Risk adjustment will require new data—Medicare Advantage and Affordable Care Act (ACA) marketplace risk adjustment rely on diagnosis codes captured during health care delivery. AI that detects conditions earlier or identifies previously unrecognized health risks will change coding patterns. Carriers should anticipate how AI deployment across their provider networks will influence risk pool composition.

  • Regulatory landscape is fragmenting—More than 250 health care AI bills were introduced across over 34 states in 2025. States like Colorado, Utah, and California have already enacted laws with varying requirements for disclosure, opt-out mechanisms, and transparency. For insurance carriers operating across multiple states, compliance complexity is increasing. The cost of compliance will vary based on geographic footprint.


What This Means for Insurance Agents: Positioning as Strategic Advisors

Your health system and provider clients are making substantial AI investments. Understanding their priorities positions you as a strategic advisor rather than a transactional intermediary.


  • Ask the right questions—When meeting with health system chief financial offerices (CFOs) and risk managers, ask about their AI roadmap. Which applications are they prioritizing, what outcomes have they measured, and how do they expect AI to affect their risk profile? These conversations surface insights about changing utilization patterns and potential exposure to new risks.

  • Understand the cost-quality trade-offs—Health systems deploying clinical AI often invest millions in technology infrastructure, vendor contracts, and staff training. Agents who understand both the upside (e.g., better outcomes, higher value-based care performance) and downside (e.g., implementation risks, vendor dependencies, regulatory compliance) can structure coverage that reflects the complete picture.

  • Connect clients with value-based opportunities—Many health systems pursue AI to succeed in value-based contracts but lack strong relationships with payers who offer these arrangements. Agents who can facilitate these connections create value beyond that of the traditional brokerage.


What This Means for Digital Marketers: Content That Resonates in a Skeptical Market

Health systems are actively seeking AI solutions, but have become sophisticated buyers. After years of vendor pitches promising transformation, decision-makers demand proof.


  • Lead with evidence, not innovation theater—Mayo Clinic, Tampa General Hospital, and Henry Ford Health didn't deploy AI because it was innovative; they deployed it because they had evidence that it would work. Case studies demonstrating real-world results resonate far more than generic innovation messaging. Specific metrics matter: 68% mortality reduction, 438-day earlier detection, 76% workload reduction.

  • Address integration challenges head-on—Health systems know that AI deployment is hard. Content that addresses workflow disruption, alert fatigue, staff training requirements, and interoperability challenges shows that you understand the buyer's reality. Most vendors avoid these topics so differentiation comes from tackling them directly.

  • Highlight governance and compliance capabilities—With state AI regulations fragmenting and health systems increasingly concerned about liability, solutions that include robust governance frameworks have competitive advantage. Content explaining how your AI tools support transparency, enable human oversight, and document decision-making addresses real executive concerns.

  • Provide peer-reviewed validation where possible—The State of Clinical AI report emphasized the gap between controlled research performance and real-world outcomes. AI tools with peer-reviewed studies demonstrating clinical effectiveness in prospective trials carry more weight. If your solution has published research, you should feature it prominently.


Regulatory Wild Card: Navigating State-by-State Complexity

The regulatory environment for health care AI is evolving rapidly, creating both challenges and opportunities.


Federal Deregulation Meets State Action

The Trump administration's December 2025 executive order aimed to reduce AI regulation and create a national framework, but states continue enacting their own requirements. This creates tension between federal deregulation goals and state-level patient protection mandates.


The Office of the National Coordinator for Health Information Technology (ONC) proposed a rule in December 2025 that would remove AI "model card" certification requirements, signaling federal intent to streamline approval processes. However, states like Texas and California are moving in the opposite direction with transparency and disclosure mandates effective January 2026.


Compliance Becomes a Competitive Moat

As regulations tighten, organizations that build a robust compliance infrastructure for AI governance will have competitive advantage. This means tracking AI use across workflows, documenting decision-making processes, and maintaining transparency about algorithmic determinations.


For insurers, this means evaluating not just what AI tools do, but how vendor compliance capabilities align with emerging requirements. For agents, it means understanding which clients face higher regulatory risk based on their geographic footprint and AI deployment strategies. And for marketers, it means positioning compliance capabilities as a key product differentiator.


Path Forward: Bold Reinvention or Incremental Evolution?

Health care faces a choice between bold reinvention and incremental evolution in AI deployment.


The bold path involves rapid clinical AI adoption, significant workflow redesign, and tolerance for implementation challenges in pursuit of transformative outcomes. Tampa General Hospital's 68% mortality reduction and Mayo Clinic's three-year early detection windows exemplify what's possible with aggressive deployment.


The incremental path focuses on proven administrative applications while carefully testing clinical tools through extensive pilots. This approach minimizes disruption, but may concede competitive advantage to faster-moving systems.


Most health systems will chart a middle course: aggressive deployment for administrative AI with clear ROI, cautious expansion into clinical applications with robust evidence. This measured approach creates opportunity for stakeholders who can identify which clinical AI applications have sufficient validation to warrant early adoption.


Stakes Are Higher Than Efficiency Gains

The health care AI conversation often focuses on efficiency, cost reduction, and administrative burden. These matter, but they miss the larger point.


Tampa General Hospital saved nearly 800 lives. Mayo Clinic is detecting pancreatic cancer years before traditional methods. Henry Ford Health is preventing adverse drug reactions before patients experience them.


These outcomes transcend efficiency; they represent fundamental improvements in care quality. For insurance carriers, this means that AI is about enabling better outcomes that reduce long-term medical spending while improving member satisfaction and quality metrics. 


For agents, it's about helping clients succeed in value-based arrangements by partnering with high-performing providers. And for marketers, it's about communicating how AI enables the "holy grail of health care": better outcomes at lower cost.


We know that clinical AI is transforming health care as Tampa General Hospital, Mayo Clinic, and others have demonstrated that transformation is underway. The question is how quickly stakeholders across the insurance and marketing ecosystem can adapt their strategies, operations, and business models to this new reality.


Those who view AI as an incremental improvement tool will be left behind. Those who recognize it as a fundamental restructuring of health care delivery, diagnosis, and treatment will position themselves to thrive in the next decade of health care evolution.


Sources:



Further Thoughts

The evidence is conclusive: clinical AI has moved from promise to practice, from theory to measurable impact on patient lives. When Tampa General Hospital saves 800 lives through AI-powered sepsis monitoring, when Mayo Clinic detects pancreatic cancer three years before traditional methods, and when Henry Ford Health prevents adverse drug reactions before they occur, we're witnessing a fundamental shift in health care delivery.


For insurance carriers, actuarial models built on historical disease progression patterns will need recalibration. For insurance agents, understanding client AI strategies has become essential to providing strategic value. For digital marketers, it's clear that evidence beats innovation theater. The regulatory landscape will remain fragmented, but organizations building robust AI governance now will find compliance easier than those forced into reactive adaptation.


The question facing all health care ecosystem stakeholders is whether they'll lead, follow, or be left behind by transformation. The choice is yours; the transformation is already underway.


Follow us on LinkedIn and become a member to connect with fellow Insurance Marketing Coalition (IMC) members.


Recent Posts

See All
Voice of the Coalition: Death of an AOR

AOR displacement is not a small administrative issue. It can disrupt member care, create confusion, and weaken trust across the Medicare ecosystem. Join us on Wednesday, March 25 at 11:00 AM ET for Vo

 
 
 

Comments

The IMC Blog

bottom of page